A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

医学 依维莫司 心肌梗塞 支架 心脏病学 内科学 临床终点 冠状动脉疾病 心绞痛 血管内超声 不稳定型心绞痛 药物洗脱支架 外科 临床试验 经皮冠状动脉介入治疗
作者
Patrick W. Serruys,Bernard Chevalier,Dariusz Dudek,Ángel Cequier,Didier Carrié,Andrés Iñíguez,Marcello Dominici,René J. van der Schaaf,Michael Haude,Luc Wasungu,Susan Veldhof,Lei Peng,Peter Stæhr,Maik J. Grundeken,Yutaka Ishibashi,Héctor M. García‐García,Yoshinobu Onuma
出处
期刊:The Lancet [Elsevier BV]
卷期号:385 (9962): 43-54 被引量:492
标识
DOI:10.1016/s0140-6736(14)61455-0
摘要

Despite rapid dissemination of an everolimus-eluting bioresorbable scaffold for treatment for coronary artery disease, no data from comparisons with its metallic stent counterpart are available. In a randomised controlled trial we aimed to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent. Here we report secondary clinical and procedural outcomes after 1 year of follow-up.In a single-blind, multicentre, randomised trial, we enrolled eligible patients aged 18-85 years with evidence of myocardial ischaemia and one or two de-novo native lesions in different epicardial vessels. We randomly assigned patients in a 2:1 ratio to receive treatment with an everolimus-eluting bioresorbable scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) or treatment with an everolimus-eluting metallic stent (Xience, Abbott Vascular, Santa Clara, CA, USA). Randomisation was stratified by diabetes status and number of planned target lesions. The co-primary endpoints of this study are vasomotion (change in mean lumen diameter before and after nitrate administration at 3 years) and difference between minimum lumen diameter (after nitrate administration) after the index procedure and at 3 years. Secondary endpoints were procedural performance assessed by quantitative angiography and intravascular ultrasound; composite clinical endpoints based on death, myocardial infarction, and coronary revascularisation; device and procedural success; and angina status assessed by the Seattle Angina Questionnaire and exercise testing at 6 and 12 months. Cumulative angina rate based on adverse event reporting was analysed post hoc. This trial is registered at ClinicalTrials.gov, number NCT01425281.Between Nov 28, 2011, and June 4, 2013, we enrolled 501 patients and randomly assigned them to the bioresorbable scaffold group (335 patients, 364 lesions) or the metallic stent group (166 patients, 182 lesions). Dilatation pressure and balloon diameter at the highest pressure during implantation or postdilatation were higher and larger in the metallic stent group, whereas the acute recoil post implantation was similar (0.19 mm for both, p=0.85). Acute lumen gain was lower for the bioresorbable scaffold by quantitative coronary angiography (1.15 mm vs 1.46 mm, p<0.0001) and quantitative intravascular ultrasound (2.85 mm(2)vs 3.60 mm(2), p<0.0001), resulting in a smaller lumen diameter or area post procedure. At 1 year, however, cumulative rates of first new or worsening angina from adverse event reporting were lower (72 patients [22%] in the bioresorbable scaffold group vs 50 [30%] in the metallic stent group, p=0.04), whereas performance during maximum exercise and angina status by SAQ were similar. The 1-year composite device orientated endpoint was similar between the bioresorbable scaffold and metallic stent groups (16 patients [5%] vs five patients [3%], p=0.35). Three patients in the bioresorbable scaffold group had definite or probable scaffold thromboses (one definite acute, one definite sub-acute, and one probable late), compared with no patients in the metallic stent group. There were 17 (5%) major cardiac adverse events in the bioresorbable scaffold group compared with five (3%) events in the metallic stent group, with the most common adverse events being myocardial infarction (15 cases [4%] vs two cases [1%], respectively) and clinically indicated target-lesion revascularisation (four cases [1%] vs three cases [2%], respectively).The everolimus-eluting bioresorbable scaffold showed similar 1-year composite secondary clinical outcomes to the everolimus-eluting metallic stent.Abbott Vascular.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
青柠完成签到,获得积分10
1秒前
258369发布了新的文献求助10
3秒前
Ava应助俏皮的白柏采纳,获得10
4秒前
James- LPY发布了新的文献求助10
5秒前
千余发布了新的文献求助10
8秒前
anan完成签到,获得积分10
8秒前
11秒前
11秒前
12秒前
13秒前
莹0000完成签到,获得积分10
14秒前
15秒前
YamDaamCaa应助科研通管家采纳,获得30
16秒前
YamDaamCaa应助科研通管家采纳,获得30
17秒前
桐桐应助科研通管家采纳,获得10
17秒前
17秒前
烟花应助科研通管家采纳,获得10
17秒前
星辰大海应助科研通管家采纳,获得10
17秒前
17秒前
moon发布了新的文献求助10
17秒前
幽默尔蓝发布了新的文献求助10
17秒前
默默的裘完成签到,获得积分10
19秒前
科研通AI2S应助liuzengzhang666采纳,获得10
20秒前
深情安青应助lll采纳,获得10
21秒前
闪闪完成签到,获得积分10
22秒前
AST灰烬发布了新的文献求助10
22秒前
23秒前
鲤跃发布了新的文献求助10
25秒前
26秒前
27秒前
情怀应助moon采纳,获得10
27秒前
27秒前
lll应助文件撤销了驳回
30秒前
30秒前
陈七七完成签到 ,获得积分10
31秒前
32秒前
33秒前
34秒前
小二郎应助房山季鸟猴采纳,获得10
34秒前
35秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988868
求助须知:如何正确求助?哪些是违规求助? 3531255
关于积分的说明 11253071
捐赠科研通 3269858
什么是DOI,文献DOI怎么找? 1804822
邀请新用户注册赠送积分活动 881994
科研通“疑难数据库(出版商)”最低求助积分说明 809035